Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CD4-Directed Chimeric Antigen Receptor T-cells for the Treatment of Patients with Relapsed or Refractory CD4+ Hematologic Cancers

Trial Status: temporarily closed to accrual

This phase I trial tests the safety, side effects, and best dose of CD4-directed chimeric antigen receptor engineered T cells (CD4CAR) in treating patients with CD4+ leukemia or lymphoma that has come back (relapsed) or that does not respond completely to treatment (refractory). CD4CAR is a type of chimeric antigen receptor (CAR) T cell therapy. CAR T cell therapy uses the body's own immune cells, called T cells, to try and kill cancerous cells. T cells fight infections and can also kill cancer cells in some cases. T cells will be removed from blood, changed in a laboratory, and then given back by intravenous infusion. While in the laboratory, new genetic material will be put into the T cells using a virus. T cells that have genetic material added are called genetically changed T cells. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill them.